Earnings results for Cogent Biosciences (NASDAQ:COGT)
Cogent Biosciences, Inc. is estimated to report earnings on 08/17/2021. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.39. The reported EPS for the same quarter last year was $-0.96.
Cogent Biosciences last announced its earnings data on May 11th, 2021. The technology company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by $0.06. Cogent Biosciences has generated ($16.08) earnings per share over the last year (($12.43) diluted earnings per share). Earnings for Cogent Biosciences are expected to decrease in the coming year, from ($1.45) to ($1.61) per share. Cogent Biosciences has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Tuesday, August 17th, 2021 based off prior year’s report dates.
Analyst Opinion on Cogent Biosciences (NASDAQ:COGT)
5 Wall Street analysts have issued ratings and price targets for Cogent Biosciences in the last 12 months. Their average twelve-month price target is $17.50, predicting that the stock has a possible upside of 117.93%. The high price target for COGT is $24.00 and the low price target for COGT is $4.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Cogent Biosciences has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $17.50, Cogent Biosciences has a forecasted upside of 117.9% from its current price of $8.03. Cogent Biosciences has received no research coverage in the past 90 days.
Dividend Strength: Cogent Biosciences (NASDAQ:COGT)
Cogent Biosciences does not currently pay a dividend. Cogent Biosciences does not have a long track record of dividend growth.
Insiders buying/selling: Cogent Biosciences (NASDAQ:COGT)
In the past three months, Cogent Biosciences insiders have not sold or bought any company stock. Only 0.86% of the stock of Cogent Biosciences is held by insiders. 93.31% of the stock of Cogent Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.
Earnings and Valuation of Cogent Biosciences (NASDAQ:COGT
Earnings for Cogent Biosciences are expected to decrease in the coming year, from ($1.45) to ($1.61) per share. The P/E ratio of Cogent Biosciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Cogent Biosciences is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Cogent Biosciences has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here